

NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model

LIDDS has successfully completed another preclinical study in mice assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy. Clear anti-tumor effects have been observed in another cancer model in mice where significant decreases in tumor growth was demonstrated.

LIDDS has several projects ongoing that focus on assessing the feasibility of using the NanoZolid-technology for local or intratumoral immunotherapy. These studies aim at a local intratumoral delivery of an immune-stimulatory agent.

The confirmed anti-tumor effect of an immune-stimulating agent formulated using the NanoZolid-technology in two independent cancer models in mice, will trigger the initiation of follow-on studies. The possibility that local immune-stimulation using the NanoZolid-technology will increase the effects of systemic immunotherapy will be investigated. Results are expected during the next four months.

A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. Successful combination treatments could significantly increase the response rates and efficacy rates of current immunotherapies. As immuno-oncology is the fastest growing area in oncology, reaching a market size over 100 billion USD by 2022, these results should be of great interest to pharmaceutical companies seeking new combination modalities to increase the response rate and efficacy of their immunotherapy drugs.

A recent review article in the highly ranked journal *Annals of Oncology* highlights the unique opportunity of intratumoral treatments to increase the efficacy of immunotherapy while reducing the potential side-effects, <https://doi.org/10.1093/annonc/mdx683>.

Immunotherapy for the treatment of cancer aims to activate and utilize the body's own immune system to recognize and attack tumors and cancer cells and is today the most promising area of cancer research.

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.com

LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 10 January 2018 at 15.00 CET.

About LIDDS

LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company's most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to www.liddspharma.com.